All posts by medical

Neuroscience

Tools for neuroscience research – Scientist Live

Amsbio has published a new 25-page Neuroscience catalogue that details its extensive range of specific tools and reagents to enable researchers stay at the forefront of their field.

Cellular models are key tools that open the door to numerous neuroscience applications including neurodegeneration, neurogensis and developmental diseases.

With the discovery that neural stem cells exist in the adult brain many researchers are now seeking to use these cells in in vitro studies.

To restore normal function in numerous disorders, including Parkinson's Disease and Alzheimers Disease, neural stem cell transplantation is an important emerging strategy.

Furthermore, the recent advent of iPSC and genome editing technology, including CRISPR, has transformed the scope of neuroscience research allowing the generation of isogenic models and the ability to obtain large numbers of neural stem cells, which had been traditionally difficult to obtain.

As many researchers acknowledge the importance of studying the behaviour of neurons, glial cells and neural stem cells with a physiologically relevant context the importance of 3D cell culture has grown.

Beautifully illustrated the new catalogue provides detailed information on the latest neural stem cells, cell culture media/supplements, matrices, scaffolds, cryopreservation media and neural transfection products available from Amsbio.

Link:
Tools for neuroscience research - Scientist Live

Immunology

Frontier Pharma: Versatile Innovation in Immunology – Substantial Deal Making Activity Observed Over the Past … – Yahoo Finance

DUBLIN, Feb 15, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential" drug pipelines to their offering.

Research and Markets Logo

Immunology is a large therapy area characterized by disorders of the immune system - specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and loss of mobility, and have a negative impact on quality of life.

This disease area has a total of 2,145 products in active development, trailing only oncology, infectious diseases and central nervous system disorders in terms of pipeline size. There are a total of 529 immunology pipeline products that act on first-in-class molecular targets, representing approximately 40% of the total immunology pipeline for which the molecular target was disclosed.

Due to a degree of crossover between immunology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

Approximately one-fifth of first-in-class pipeline products are in development for two or more indications within the therapy area. This presents an opportunity for companies to develop innovative products across multiple immune disorders, and therefore reach a larger pool of patients than products developed for single indications.

Key Topics Covered:

1 Table of Contents

2 Executive Summary

2.1 Large Therapy Area Characterized by a High Degree of Pathophysiological Crossover

2.2 Strong Pipeline Shows High Level of Versatile Innovation

2.3 Substantial Deal Making Activity Observed over the Past Decade

3 The Case for Innovation in the Immunology Market

3.1 Growing Opportunities for Biologic Products

3.2 Diversification of Molecular Targets

3.3 Innovative First-in-Class Product Developments Remain Attractive

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation

3.5 Sustained Innovation

4 Introduction

4.1 Therapy Area Introduction

4.2 Symptoms

4.3 Etiology and Pathophysiology

4.3.1 Innate Immunity

4.3.2 Adaptive Immunity

4.3.3 The Role of Cytokines

4.3.4 Autoimmunity

4.3.5 Etiologic Factors for Autoimmunity and Allergies

4.3.6 Conclusion

4.4 Co-morbidities and Complications

4.5 Epidemiology

4.6 Treatment

4.6.1 Non-Biologic Disease-Modifying Anti-Rheumatic Drugs

4.6.2 Glucocorticoids

4.6.3 Biologics and Targeted Therapies

5 Pipeline Landscape Assessment

5.1 Overview

5.2 Pipeline Development Landscape

5.3 Molecular Targets in the Pipeline

5.4 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family

5.5 First-in-Class and Versatile Pipeline Programs

5.6 First-in-Class Immunology Products by Phase, Molecule Type and Molecular Target

5.7 Versatility of First-in-Class Pipeline Products

6 Immunology Signaling Network, Disease Causation and Innovation Alignment

6.1 Complexity of Signaling Networks

6.2 Signaling Pathways and First-in-Class Molecular Target Integration

6.3 First-in-Class Matrix Assessment

7 First-in-Class Target and Pipeline Program Evaluation

Read More

7.1 Pipeline Programs Targeting Toll-Like Receptors 3, 6 and 8

7.2 Pipeline Programs Targeting Spleen Tyrosine Kinase

7.3 Pipeline Programs Targeting IL-7R

7.4 Pipeline Programs Targeting C-C Chemokine Receptor Type 6

7.5 Pipeline Programs Targeting P2RX7

7.6 Pipeline Programs Targeting ITK

7.7 Pipeline Programs Targeting IRAK4

7.8 Pipeline Programs Targeting Orai1

7.9 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5

7.10 Conclusion

8 Strategic Consolidations

8.1 Industry-Wide First-in-Class Deals

8.2 Licensing Deals

8.2.1 Deals by Region, Year and Value

8.2.2 Deals by Stage of Development and Value

8.2.3 Deals by Molecule Type and Value

8.2.4 Deals by Molecular Target and Value

8.3 Co-development Deals

8.3.1 Deals by Region, Year and Value

8.3.2 Deals by Stage of Development and Value

8.3.3 Deals by Molecule Type and Value

8.3.4 Deals by Molecular Target and Value

8.4 List of First-in-Class Pipeline Products with and Without Prior Deal Involvement

9 Appendix

9.1 Abbreviations

9.2 References

9.3 Research Methodology

9.3.1 Data integrity

9.3.2 Innovative and meaningful analytical techniques and frameworks

9.3.3 Evidence based analysis and insight

9.4 Secondary Research

9.4.1 Market Analysis

9.4.2 Pipeline Analysis

9.4.3 Licensing and Co-development Deals

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/lgc9s8/frontier_pharma

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/frontier-pharma-versatile-innovation-in-immunology---substantial-deal-making-activity-observed-over-the-past-decade---research-and-markets-300407842.html

Read this article:
Frontier Pharma: Versatile Innovation in Immunology - Substantial Deal Making Activity Observed Over the Past ... - Yahoo Finance

Genetics

Ovarian Cancer and Genetics – News-Medical.net

Women who have a strong family history of breast or ovarian cancer are more likely to be affected by cancer of the ovaries, fallopian tube, or peritoneal cavity. This is thought to be due to a mutation in one of the genes that are involved in the regulation of cell growth and replication in these areas, which can be inherited from the parents.

It is estimated the 10-15% of ovarian, fallopian tube, or peritoneal cancers are associated with an inherited genetic mutation. The remaining majority of cases of cancer are linked to a genetic mutation that is acquired by the individual in their lifetime.

The BReast CAncer 1 (BRCA1) and BReast CAncer 2 (BRCA2) genes have been identified as genes that are linked to an increased risk of the development of both breast cancer and ovarian cancer. Everybody possesses these genes in their body because they play an important role in the regulation of cell growth in the breasts and ovaries, but a mutation in one or both of these genes increases the likelihood that an individual will be affected by breast or ovarian cancer.

A woman with a mutation in the BRCA2 gene has a lifetime risk of 10-20% of developing ovarian cancer. This is approximately ten times higher that the risk of an average woman, which is 1-2%.

Other genes that have been linked to an increased risk of ovarian cancer include:

There are various genetic conditions that are linked to an increased risk of ovarian cancer development. These include:

For women who have a raised risk of ovarian cancer due to the inheritance of a gene that is linked to causing the condition, there are several steps that can be taken to reduce their risk.

For example, some women may choose to have their ovaries and fallopian tubes to be removed. This helps to reduce the risk of cancer in these areas, as well as the risk of some types of breast cancer due to decreased production of estrogen, which usually occurs in the ovaries. The risk of ovarian cancer can be reduced by 70-96% and the risk of breast cancer by 40-70%.

However, this surgical procedure should not be considered unless a woman is certain that she does not wish to bear any children in the future because the removal of the ovaries will render her infertile.

Genetic testing is available for women with a strong family history of breast or ovarian cancer to detect mutations in the genes that are known to raise the risk of cancer. It is important for patients to be aware of the benefits and negative aspects of being tested before they undergo the examination.

Reviewed by Susha Cheriyedath, MSc

More here:
Ovarian Cancer and Genetics - News-Medical.net

Genetics

Clemson Center for Human Genetics unveils new facility on Greenwood Genetic Center campus – Clemson Newsstand

GREENWOOD Self Regional Hall, a new 17,000-square-foot, state-of-the art facility that will house the Clemson University Center for Human Genetics, has opened on the campus of the Greenwood Genetic Center.

Self Regional Hall, a new 17,000-square-foot, state-of-the art facility that will house the Clemson University Center for Human Genetics. Image Credit: Craig Mahaffey / Clemson University

The facility will enable Clemsons growing genetics program to collaborate closely with the long tradition of clinical and research excellence at the Greenwood Genetic Center, combining basic science and clinical care. The center will initially focus on discovering and developing early diagnostic tools and therapies for autism, cognitive developmental disorders, oncology and lysosomal disorders.

Opening Self Regional Hall means that we will be able to do even more to help children with genetic disorders, and their families, and to educate graduate students who will go out into the world and make their own impact, said Clemson University President James P. Clements.

As the parent of a child with special needs the kind of research that you are doing here is especially meaningful and important to me and my family, Clements said during the event. As you all know, an early diagnosis can make a huge difference for a child and their family because the earlier you can figure out what a child needs the earlier you can intervene and begin treatment.

Jim Pfeiffer (left), president and CEO of Regional Healthcare, and Clemson President James P. Clements unveil a commemorative plaque. Image Credit: Craig Mahaffey / Clemson University

According to the Centers for Disease Control and Prevention, one in six children between the ages of 3 and 17, roughly 15 percent, suffers from a developmental disorder.

Self Regional Hall is a state-of-the-art facility that provides the resources our scientists need to understand the genetic underpinnings of disorders, said Mark Leising, interim dean of the College of Science at Clemson. This facility, and its proximity to the Greenwood Genetic Center, elevates our ability to attract the brightest scientific talent to South Carolina and enhances our efforts to tackle genetic disorders.

The building will house eight laboratories and several classrooms, conference rooms and offices for graduate students and faculty.

The facilitys name recognizes the ongoing support from Self Regional Healthcare, a healthcare system in Upstate South Carolina that has grown from the philanthropy of the late James P. Self, a textile magnate who founded Self Memorial Hospital in 1951.

The ribbon-cutting ceremony was originally scheduled for September 2016, but was delayed because of the death of state Sen. John Drummond, an ardent supporter of the Greenwood Genetic Center who helped bring Self Regional Hall to fruition.

Image Credit: Craig Mahaffey / Clemson University

Self Regional Healthcares vision is to provide superior care, experience and value. This vision includes affording our patients with access to cutting-edge technology and the latest in healthcare innovation and genomic medicine, without a doubt, is the future of healthcare, said Jim Pfeiffer, president and CEO of Self Regional Healthcare. The research and discoveries that will originate from this center will provide new options for those individuals facing intellectual and developmental disabilities, and will provide our organization with innovative capabilities and treatment options for our patients.

We are pleased to welcome Clemson University to Greenwood as the first academic partner on our Partnership Campus, added Dr. Steve Skinner, director of the Greenwood Genetic Center. This is the next great step in a collaboration that has been developing over the past 20-plus years. We look forward to our joint efforts with both Clemson and Self Regional Healthcare to advance the research and discoveries that will increase our understanding and treatment of human genetic disorders.

END

Greenwood Genetic CenterThe Greenwood Genetic Center (GGC), founded in 1974, is a nonprofit organization advancing the field of medical genetics and caring for families impacted by genetic disease and birth defects. At its home campus in Greenwood, South Carolina, a talented team of physicians and scientists provides clinical genetic services, diagnostic laboratory testing, educational programs and resources, and research in the field of medical genetics.GGCs faculty and staff are committed to the goal of developing preventive and curative therapies for the individuals and families they serve.GGC extends its reach as a resource to all residents of South Carolina with satellite offices in Charleston, Columbia, Florence and Greenville. For more information about GGC, please visitwww.ggc.org.

Original post:
Clemson Center for Human Genetics unveils new facility on Greenwood Genetic Center campus - Clemson Newsstand

Cell Biology

George Klein (19252016) – Nature.com

Gunnar Ask

George Klein, with his wife, Eva, discovered foundational phenomena in cancer research. He showed that normal cells carry genes, now known as tumour suppressors, that prevent cancer. He also worked out how the immune system comes to recognize and eliminate cancer cells.

Klein, who died on 10 December at the age of 91, had a youth filled with daring and peril. From a HungarianJewish family, he escaped being sent to a Nazi labour camp and from Russian patrols during the Second World War. He began medical studies in Budapest at the end of the war. In 1947, against all odds, a well-connected colleague arranged for Klein and a few other students to visit universities in Sweden. He was offered a place in the laboratory of the renowned cell biologist Torbjrn Caspersson at the Karolinska Institute.

Klein risked a return to communist Hungary to marry Eva, a fellow medical student he had known for mere weeks, and brought her back with him. The necessary documents typically took months to assemble, but he and Eva acquired them over a single workday using persuasion, pluck and bribes. They completed their PhDs at the Karolinska and maintained research groups there until about a month before George's death.

In 1957, a chair was created for him in tumour biology, a research field that he had helped to establish. The department of tumour biology that ensued was international and influential. Most of today's leading cancer researchers who are over 50 have had some interaction with George and his department. Seven secretaries wrangled his large correspondence. He invented social media before the technology existed.

A seminal paper published in 1960 (G. Klein et al. Cancer Res. 20, 15611572; 1960) dissected the essential basis of modern tumour immunology. Before it, researchers thought that all cancers carried a common antigen that the immune system could recognize. The Kleins and their colleagues used a chemical carcinogen to induce tumours in mice, surgically removed these and immunized the animals with irradiated cells from their own tumours. Next, the group inoculated mice with viable cancer cells and demonstrated that the immune system would only reject cancerous cells if they came from the original tumour.

This clarified the field: the immune system could recognize and reject cancers, in a way that was specific to each individual. A year later, Klein's team wrote a paper showing the other side of the coin (H. O. Sjgren et al. Cancer Res. 21, 329337; 1961). Tumours caused by the mouse polyomavirus do indeed share a common antigen. This paved the way for the general observation that tumours caused by or carrying viruses share common antigens that the immune system can target.

The Kleins' experimental success rested on two cornerstones. One was the establishment of a large colony of inbred mouse strains essential for tumour transplantation studies. After an early sabbatical at the Fox Chase Cancer Center in Philadelphia, George brought back 200 inbred mice on the return flight to found the colony.

The other was that the Kleins were among the first to apply concepts of population dynamics to cancer cells. This approach led to the demonstration of genes for tumour suppression (with their colleague at the Karolinska Francis Wiener and cell biologist Henry Harris) in the 1970s, at a time when it was not even clear that cancer had a genetic basis. This anticipated the modern view of cancer as resulting from the Darwinian evolution of cancer cells. Consecutive mutations in multiple genes increased the ability of wayward cells to survive, proliferate and evade checks against their growth.

Other seminal contributions included the prediction that translocations between chromosomes could activate oncogenes and the discovery of the Epstein-Barr virus nuclear proteins, which are crucial in the viral transformation of normal cells to a cancerous state. Their team (with Rolf Kiessling, then a graduate student at the Karolinska) also discovered, in 1975, natural killer cells, which can eliminate both cancerous and infected cells.

George showed an unusually high intellectual presence that mesmerized younger researchers. The tumour-biology department broke the boundaries of classic disciplines: it integrated genetics and mouse studies with cell biology, immunology and the study of infectious agents.

George also published books on the humanities, philosophy and popular science. Topics ranged from the Holocaust, atheism and religion to mysteries in cell biology and personal portraits of his heroes in science, music, poetry and literature. He was a leading public intellectual, often on Swedish television and in newspapers. His last book, Resistance (Albert Bonniers Frlag, 2015; published in Swedish), won the prestigious Gerard Bonnier prize for the best essay collection of that year. It deals with resistance to extremism and to cancer. Throughout his life, George was preoccupied with the thin borders between evil and good, and health and disease.

He was an admired lecturer for general and scientific audiences. His preferred format was conversation with an interesting opponent. There was a time when most major international cancer conferences concluded with his creative remarks. Many are those who can witness how much they were affected by bouncing ideas and results around with George.

Read more from the original source:
George Klein (19252016) - Nature.com

Biochemistry

Chemistry Seminar by Fr. Gerald Buonopane – Seton Hall University News & Events

Wednesday, February 15, 2017

By Nicholas Snow

The Department of Chemistry and Biochemistry Rose Mercadante Seminar Series is pleased to present a seminar entitled "Effect of Cold Plasma Processing on Sweet Basil and the Chemistry of its Essential Oils" by Fr. Gerald Buonopane, Dr. Cosimo Antonacci and Dr. Jose Lopez of the Departments of Chemistry and Biochemistry and Physics of Seton Hall University.

The seminar will take place in the Helen Lerner Amphitheater, Science and Technology Center, Seton Hall University at 5:45 P.M. on Tuesday February 21, 2017. Refreshments are available at 5:30 PM.

This interdisciplinary research project, which focuses on the emerging field of plasma agriculture, seeks to better understand the chemical and physical effects of cold plasma processing on plants and their essential oils. Cold plasma processing has been shown to be a rapid, economical, and pollution-free method to improve plant seed performance and crop yield. Essential oils are aromatic oily liquids extracted from different parts of plants, such as the leaves, flowers, and roots. Among the various beneficial properties of essential oils is their demonstrated antioxidant effect directly applicable to foods that are prone to oxidative consequences such as poor flavor, bad odors, and spoilage. Antioxidants, either synthetic (e.g., butylated hydroxytoluene, BHT) or natural (e.g., Vitamin C), are routinely added to processed foods to inhibit or delay oxidation. Essential oils are examples of natural antioxidants. Although synthetic antioxidants like BHT and BHA (butylated hydroxyanisole) are very effective, they have been shown to be potentially harmful to human health with demonstrated evidence of causing cancer in laboratory animals. As a result, food scientists have been seeking alternative natural compounds as substitute antioxidants, such as essential oils. We have observed a growth effect in our preliminary studies treating basil plants with cold plasmas. We have also observed that plasma treatment increases the antioxidant activity of essential oils. Our preliminary work further revealed a difference in the composition of individual antioxidant components between the plasma-treated and non-plasma-treated basil. In follow-up studies, we seek to better understand cold plasma's physical and biochemical-molecular effects on basil plants.

Ordained as a priest of the Archdiocese of Newark in 2006, Fr. Gerry's area of specialization is food chemistry. He earned a B.S. in Biology from Northeastern University (1978), a M.S. in Nutritional Science from the University of Connecticut (1981) and a Ph.D. in Food Science from Penn State University (1988). Prior to seminary and the priesthood, Fr. Gerry held a number of positions in academia, the federal government (USFDA), and in the food and pharmaceutical industries. His research areas of interest are: Chemical Deterioration of Food Lipids: Oxidative Reactions; Essential Oils as Natural Antioxidants; and Cold Plasma Treatment of Botanicals and Essential Oils.

Dr. Cosimo Antonacci holds BS and PhD degrees in Chemistry from Seton Hall University. He is currently Undergraduate Laboratory Manager in the Department of Chemistry and Biochemistry, where he supervises all activities in the department's teaching laboratories. He is an active researcher in biochemistry with ongoing collaborations in Biochemistry, Biological Sciences and Physics.

Professor Jose L. Lopez is an Associate Professor in the Department of Physics at Seton Hall University in South Orange, New Jersey, USA. He earned a B.S. in Physics from Saint Peter's University in Jersey City, New Jersey in 2000, an M.S. in Physics in 2003 and a Ph.D. in Physics in 2006 from the Stevens Institute of Technology in Hoboken, New Jersey.

Categories: Science and Technology

For more information, please contact:

Visit link:
Chemistry Seminar by Fr. Gerald Buonopane - Seton Hall University News & Events

Anatomy

Study Explores ‘Anatomy Of An Auto Shopper’ – MediaPost Communications

Luxury car drivers do not behave the same way as drivers in other segments when they are off the road, according to a study released Feb. 15.

One surprising statistic was that luxury car shoppers were 55% more likely to frequent Costco than non-luxury car shoppers," says Jon Schulz, CMO of Viant. Conventional wisdom might lead folks to assume that non-luxury car shoppers would have a higher penetration at a warehouse discount store like Costco.Retail habits can often surprise even the most seasoned advertising professional.It definitely pays to do your homework here.

Viants "Anatomy of an Auto Shopper" explores the unique characteristics of four key shopper segments: luxury car, non-luxury car, utility vehicles (CUV/SUV), and truck.

advertisement

advertisement

The report covers everything from make/model/brand affinities by ethnic groups to how these preferences impact shopping habits (CPG products and retail location).

The utility segment is surging as the car segment continues to hover near historic lows.Eighty-two percent of respondents age 35+ are utility drivers, compared to 67% of car drivers and 69% of truck drivers. Nearly two-thirds of these customers prefer domestic brands, which spells opportunity for some and a challenge for others.Given the rapid growth, this is clearly a group that auto marketers want to get much more familiar with, Schulz tells Marketing Daily.

Since they are migrating from non-luxury car, they share some traits, but also have some very unique characteristics which make them a bit more challenging to pinpoint, he adds.

The top utility vehicle choice among African Americans, Caucasians, and Hispanics is the Ford Explorer, whileAsians favor the Honda Odyssey.For the luxury car segment, the top choice for Asians, Caucasians, and Hispanics is the BMW 3-Series, whileAfrican Americans prefer the Cadillac CTS.The Honda Accord is the most prevalent non-luxury car for all ethnicities.

Marketers are already sold on the accuracy and targeting of people-based marketing, but thats only been available within a few walled gardens. Giving them the ability to now target like this across the open Web, where people are spending the majority of their time, will help move the needle for marketers, Schulz says.

For example, understanding grocery product or retailer preferences, and actual transactional datacan inform partnership opportunities and/or cross-promotion, Schulz says. Certainly, TV viewing habits of targeted shoppers can inform media plans and better align spending not only on TVbut across all channels, to the actual behaviors of desired customer segments. There is still an art to advertising, but adding deterministic data into the mix makes approaches more scientific and measurable.

One automaker that appears to already be mindful of these findings is Nissan.

We cited a Nissan example in the study around their efforts to grow share with the Hispanic auto buying market, Schulz said. These types of highly targeted campaigns with custom creative drive measurable results. It is definitely easier to simply run a few different creative messages to everyone, it just doesnt provide the same impact.Audience segments can behave very differently and require custom approaches.

There is a definitive shift among consumers away from traditional broadcast and cable television consumption to streaming services, OTT and online video.

Our study reinforces the shift to live sports and news programming and away from more traditional prime-time programming for both better audiences and to minimize the DVR impact, Schulz says. TV still commands a large pool of advertising dollars despite falling ratings and high cost per point.

Big television platforms like the Super Bowl have experienced declining viewership over the last two years, yet the cost of a 30-second ad has gone up over 10% in that time period.

You see similar patterns where programs are getting fewer viewers, yet the cost is increasing, Schulz says. This will not last, as more advertisers are focused on ROI from their advertising spend and thus are starting to shift to mobile and other platforms where the users are spending their time.

Read more from the original source:
Study Explores 'Anatomy Of An Auto Shopper' - MediaPost Communications

Anatomy

Grey’s Anatomy: Minnick faces uphill battle at Grey Sloan – EW.com (blog)

Eliza Minnick hasnt made the best first impression at Grey Sloan.

Not only did Minnick (Marika Dominczyk) basically oust Richard (James Pickens Jr) as the head of the surgical residency program, but she also essentially got Meredith (Ellen Pompeo) suspended. So when Minnick implements Phase 2 of her teaching methods during Thursdays episode of Greys Anatomy, the doctors of Grey Sloan wont take it very well. EW turned to Dominczyk to get the scoop:

ENTERTAINMENT WEEKLY: Eliza is implementing her next phase of teaching. What does that entail? MARIKA DOMINCZYK: That entails 100 percent using Elizas method, which means the residents get to go to work and the attendings are way more hands-off. Its going to be like a real trial of this method that Eliza believes is tried and true, and the only way to move the hospital forward.

How will the attendings take to the next phase? Theyre not going to like it. Its going to take a little bit of arm twisting to get there. Not many of them like Eliza.

What is it like for you to play a character who is so universally hated right now? Its so funnybecause,honestly, I dont look at it that way. As an actor, its so much fun to play this character for me, because Im not like Eliza, Im not Type-A. Im not Eliza, so as an actor, its been the best and so fun to walk in and do this. Greys has such an enormous fanbase that I wasnt aware of. I take it all with a grain of salt. I look at Twitter. I feel like it would be so boring if you just loved everybody all the time. Thats my personal opinion. I think its fun and I think she shakes it up a bit.

Do I think that her social graces are on point? Not necessarily. [Laughs] Would I behave the way she does? I wouldnt. But, at the end of the day, shes doing it because she super believes that her way is the best way. She got hired to do this job and shes going to do it. Eliza said, Im not here to make friends, and she believes that. Would she like to make friends? Im sure. She cant right nowbecause her No. 1 goal is to do the job she was hired for. Unfortunately, thats not a job people like her having.

Is she finding any other allies at the hospital? She kind of finds an ally slowly. It goes a little bit back and forth. Arizona (Jessica Capshaw) has been in her corner sort of, kind of. Edwards (Jerrika Hinton) really likes her there. The people that want to learn and progress have been a little more open than some others, but its still like treadingwater. Its been slow trying to get people on her side.

Do you think she can ever win the doctors over? I dont know if she can. Just like with the fans, theres so much history, I think theres so much history on the show within the hospital. I dont know if they would all be like a kumbaya, love Eliza [situation]. Shes the type of character thats not for everybody. Her bedside manner is not the best, so I dont know. I hope so.

Eliza clearly has feelings for Arizona, so whats that challenge like for her because shes hated by the doctors who side with Richard (James Pickens Jr.)? Does she feel like theres any hope for a relationship with Arizona? I think she does, and thats part of her appeal and part of why people dont like her, because she doesnt get it. For her, work is just work and this is what happens at work; people may or may not like it. When shes not at work, shes just who she is and likes who she likes, but not everybody operates that way; not everybody can separate the two. Eliza is the kind of character that believes that she can separate the two, so its no big deal. She doesnt think about maybe how others dont operate the same way.

Stay tuned after Thursdays episode for more from Dominczyk on whats next for Eliza and Arizona.Greys Anatomy airs Thursdays at 8 p.m. ET on ABC.

Go here to read the rest:
Grey's Anatomy: Minnick faces uphill battle at Grey Sloan - EW.com (blog)

Anatomy

What makes up the anatomy of the perfect Hull City player? – Hull Daily Mail

Comments(1)

We at the Hull Daily Mail have been thinking about what makes the perfect Hull City player.

So we selected ten attributes and the idea was to name the player with the best; first touch, passing, finishing, tackling, heading, power, character, intelligence, leadership and speed.

Throw them all together and collectively you have the perfect Tiger.

To get us started football writer Will Jackson names his perfect player from the current squad and we want to hear from you about who you think would go onto the perfect City player of all time. For the next week we'll be opening the voting to find out who you think is the City player who has been the best passer of a ball that you've ever seen, or who is the quickest.

To whet your appetite for that, take a look at our perfect City player using the current squad.

First touch: Sam Clucas An unsung hero, Clucas has the ability to run a game on his day, and a cracking first touch is where that all starts.

Passing: Tom Huddlestone A candidate for a few of these categories but Huddlestone's passing is arguably the best we have ever seen in a Hull City shirt.

Finishing: Abel Hernandez When he's fit and firing, Hernandez is potent in front of goal, scoring 20 goals for Steve Bruce's Hull City last season.

Tackling: Harry Maguire 'Arry has become a cult hero at City and it's easy to see why. He doesn't take any nonsense at the back, tackling anything that moves.

More news: How do City compare in relegation battle? We ask the experts

Heading: Andrea Ranocchia The Italian is 6'5'' and it tells, dominating aerial challenges. He doesn't give strikers a sniff in the air.

Power: Alfred N'Diaye He's huge. From his bullying performances we have seen so far, this guy does not lack strength.

Character: Eldin Jakupovic Never seen a character like him. His enthusiasm is infectious and I'm sure that spreads throughout the team.

Intelligence: Curtis Davies He reads the game well, and rarely has a bad game. Also a candidate for a lot of these categories.

Leadership: Michael Dawson A true leader and fundamental to have at the back. He could have almost single handedly dragged the Tigers back up last season.

Speed: Moses Odubajo A toss up between him and Kamil Grosicki, but the right back nicks it out of sheer loyalty.

More news: Paul Merson refusing to change his mind about Hull City

More:
What makes up the anatomy of the perfect Hull City player? - Hull Daily Mail

Anatomy

Promoting quality education: ‘Use of innovative methods key in teaching anatomy’ – The Express Tribune

FAISALABAD:The best way to teach modern anatomy is by combing multiple pedagogical resources to complement one another. Students appear to learn more effectively when multi-modal and system-based approaches are integrated.

This was said by experts while speaking at a national workshop on teaching and research techniques in anatomy organised by Department of Anatomy, University of Agriculture on Wednesday. The inaugural session was chaired by UAF Vice-Chancellor Dr Iqrar Ahmad Khan.

The experts said not a single teaching tool had been found to meet curriculum requirements of anatomy.

The limitation on time, trained faculty and resources for gross anatomy courses in integrated and system based curricula, have led many medical and veterinary schools to abandon costly and time consuming decision based instructions in favour of alternative methods of instructions, including prosection, medical imaging, living anatomy and multimedia resources, the experts opined.

UAF Vice-Chancellor Dr Iqrar Ahmad Khan said UAF was taking all possible measures to produce trained manpower by ensuring quality education in the country.

He said the UAF used to organise such events to raise awareness among the masses about different issues. Dean Veterinary Sciences Dr Ahrar Khan said poverty alleviation was directly linked to the agriculture and livestock sector. He said the UAF had produced 3,000 doctors and 120 PhDs in veterinary sciences so far.

Published in The Express Tribune, February 16th, 2017.

Read the original:
Promoting quality education: 'Use of innovative methods key in teaching anatomy' - The Express Tribune